Tsai, Tsen-Fang
Zheng, Min
Ding, Yangfeng
Song, Zhiqi
Liu, Quanzhong
Chen, Ying
Hu, Hanzhao
Xu, Jinhua
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
https://doi.org/10.1007/s13555-023-01037-4
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
https://doi.org/10.1136/bmjopen-2020-043666
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 30 June 2023
Accepted: 11 September 2023
First Online: 16 October 2023
Declarations
:
: Ying Chen and Hanzhao Hu are employees of Boehringer Ingelheim. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, AnaptysBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli-Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, PharmaEssentia, Pfizer Inc., and UCB Pharma. Min Zheng, Yangfeng Ding, Zhiqi Song, Quanzhong Liu, and Jinhua Xu have nothing to disclose.
: The study was performed in compliance with the clinical trial protocol that was reviewed and approved by the Independent Ethics Committees and/or Institutional Review Boards) of the participating centers, in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonization of Good Clinical Practice. All patients provided written informed consent. All authors received consent to participate in and publish the study.